Envarsus Xr

Vitiligo, Pyoderma Gangrenosum, Kidney Transplantation + 12 more

Treatment

5 FDA approvals

20 Active Studies for Envarsus Xr

What is Envarsus Xr

Tacrolimus

The Generic name of this drug

Treatment Summary

Tacrolimus (also known as FK-506 or Fujimycin) is an immunosuppressive drug used to prevent organ rejection after transplantation. It can also be used topically to treat severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and vitiligo. Tacrolimus was discovered in 1984 in a Japanese soil sample containing the bacteria Streptomyces tsukubaensis. It works by binding to the FKBP-12 protein, which inhibits the activity of an enzyme called calcineurin, which in turn reduces the activity of the immune

Prograf

is the brand name

image of different drug pills on a surface

Envarsus Xr Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Prograf

Tacrolimus

1994

138

Approved as Treatment by the FDA

Tacrolimus, also called Prograf, is approved by the FDA for 5 uses such as Kidney Transplantation and Kidney Transplant Rejection .

Kidney Transplantation

Kidney Transplant Rejection

Liver Transplant Rejection

Immunosuppressive Treatment

Kidney

Effectiveness

How Envarsus Xr Affects Patients

Tacrolimus works by blocking a protein (FKBP-12) in the body that helps activate T-Lymphocyte cells and the production of IL-2. This helps to reduce the rate of organ rejection when compared to cyclosporine. It is also used to treat eczema and other skin conditions, as it helps reduce inflammation in a similar way to steroids, although it is not as powerful. An important benefit is that it can be used directly on the face, while topical steroids cannot, as they can thin the skin on the face. On other parts of the body, topical steroids are usually the better choice

How Envarsus Xr works in the body

The exact way tacrolimus works to treat atopic dermatitis is unknown. Research has found that tacrolimus blocks T-lymphocyte activation by binding to a protein in cells and forming a complex. This complex stops the production of certain proteins that are involved in T-cell activation and the release of other proteins from skin cells. It also reduces the number of receptors on a type of cell found in the skin.

When to interrupt dosage

The endorsed portion of Envarsus Xr relies upon the determined condition, such as Vitiligo, Rejection; Transplant, Kidney and Pyoderma Gangrenosum. The measure of dosage is subject to the means of delivery (e.g. Capsule, gelatin coated - Oral or Topical) listed in the table beneath.

Condition

Dosage

Administration

Liver

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Cutaneous, Ointment - Cutaneous, Granule - Oral, Granule, for suspension - Oral, Granule, for suspension, Kit, Injection, solution, Injection, solution - Intravenous, Cream, Cream - Topical, Solution - Topical

Pyoderma Gangrenosum

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Cutaneous, Ointment - Cutaneous, Granule - Oral, Granule, for suspension - Oral, Granule, for suspension, Kit, Injection, solution, Injection, solution - Intravenous, Cream, Cream - Topical, Solution - Topical

Dermatitis, Atopic

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Cutaneous, Ointment - Cutaneous, Granule - Oral, Granule, for suspension - Oral, Granule, for suspension, Kit, Injection, solution, Injection, solution - Intravenous, Cream, Cream - Topical, Solution - Topical

Dermatitis, Atopic

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Cutaneous, Ointment - Cutaneous, Granule - Oral, Granule, for suspension - Oral, Granule, for suspension, Kit, Injection, solution, Injection, solution - Intravenous, Cream, Cream - Topical, Solution - Topical

Rheumatoid Arthritis

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Cutaneous, Ointment - Cutaneous, Granule - Oral, Granule, for suspension - Oral, Granule, for suspension, Kit, Injection, solution, Injection, solution - Intravenous, Cream, Cream - Topical, Solution - Topical

Lichen Planus, Oral

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Cutaneous, Ointment - Cutaneous, Granule - Oral, Granule, for suspension - Oral, Granule, for suspension, Kit, Injection, solution, Injection, solution - Intravenous, Cream, Cream - Topical, Solution - Topical

Chronic Graft Versus Host Disease

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Cutaneous, Ointment - Cutaneous, Granule - Oral, Granule, for suspension - Oral, Granule, for suspension, Kit, Injection, solution, Injection, solution - Intravenous, Cream, Cream - Topical, Solution - Topical

Lung

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Cutaneous, Ointment - Cutaneous, Granule - Oral, Granule, for suspension - Oral, Granule, for suspension, Kit, Injection, solution, Injection, solution - Intravenous, Cream, Cream - Topical, Solution - Topical

Psoriasis

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Cutaneous, Ointment - Cutaneous, Granule - Oral, Granule, for suspension - Oral, Granule, for suspension, Kit, Injection, solution, Injection, solution - Intravenous, Cream, Cream - Topical, Solution - Topical

Immunocompromised

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Cutaneous, Ointment - Cutaneous, Granule - Oral, Granule, for suspension - Oral, Granule, for suspension, Kit, Injection, solution, Injection, solution - Intravenous, Cream, Cream - Topical, Solution - Topical

Vitiligo

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Cutaneous, Ointment - Cutaneous, Granule - Oral, Granule, for suspension - Oral, Granule, for suspension, Kit, Injection, solution, Injection, solution - Intravenous, Cream, Cream - Topical, Solution - Topical

Kidney Transplantation

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Cutaneous, Ointment - Cutaneous, Granule - Oral, Granule, for suspension - Oral, Granule, for suspension, Kit, Injection, solution, Injection, solution - Intravenous, Cream, Cream - Topical, Solution - Topical

Prophylaxis against heart transplant rejection

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Cutaneous, Ointment - Cutaneous, Granule - Oral, Granule, for suspension - Oral, Granule, for suspension, Kit, Injection, solution, Injection, solution - Intravenous, Cream, Cream - Topical, Solution - Topical

Kidney

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Cutaneous, Ointment - Cutaneous, Granule - Oral, Granule, for suspension - Oral, Granule, for suspension, Kit, Injection, solution, Injection, solution - Intravenous, Cream, Cream - Topical, Solution - Topical

Immunosuppressive Treatment

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Cutaneous, Ointment - Cutaneous, Granule - Oral, Granule, for suspension - Oral, Granule, for suspension, Kit, Injection, solution, Injection, solution - Intravenous, Cream, Cream - Topical, Solution - Topical

Warnings

Envarsus Xr Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Tacrolimus may interact with Pulse Frequency

There are 20 known major drug interactions with Envarsus Xr.

Common Envarsus Xr Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Tacrolimus.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Tacrolimus.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Tacrolimus.

Axitinib

Major

The serum concentration of Axitinib can be increased when it is combined with Tacrolimus.

Bacillus calmette-guerin substrain russian BCG-I live antigen

Major

The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Tacrolimus.

Envarsus Xr Toxicity & Overdose Risk

Taking too much of this drug can cause serious side effects like vision problems, issues with the liver or kidneys, seizures, shaking, high blood pressure, low magnesium levels, diabetes, high potassium levels, itching, difficulty sleeping, and confusion. The lowest toxic dose in rats is 134-194 mg/kg.

image of a doctor in a lab doing drug, clinical research

Envarsus Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Envarsus Xr?

There are 147 active clinical trials analyzing the potential of Envarsus Xr to manage Oral Lichen Planus, Pyoderma Gangrenosum and refractory Rheumatoid Arthropathy.

Condition

Clinical Trials

Trial Phases

Pyoderma Gangrenosum

2 Actively Recruiting

Phase 2, Phase 3

Rheumatoid Arthritis

56 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2, Phase 4

Immunocompromised

2 Actively Recruiting

Phase 1, Not Applicable

Lichen Planus, Oral

0 Actively Recruiting

Vitiligo

7 Actively Recruiting

Phase 2, Phase 3, Phase 1

Kidney Transplantation

0 Actively Recruiting

Kidney

0 Actively Recruiting

Liver

0 Actively Recruiting

Immunosuppressive Treatment

0 Actively Recruiting

Lung

0 Actively Recruiting

Dermatitis, Atopic

0 Actively Recruiting

Prophylaxis against heart transplant rejection

0 Actively Recruiting

Psoriasis

0 Actively Recruiting

Chronic Graft Versus Host Disease

24 Actively Recruiting

Phase 4, Phase 1, Phase 2, Not Applicable, Phase 3

Dermatitis, Atopic

0 Actively Recruiting

Envarsus Xr Reviews: What are patients saying about Envarsus Xr?

4

Patient Review

2/21/2020

Envarsus Xr for Prevent Kidney Transplant Rejection

I've been on this medication for two months and have experienced slight tremors.

3.7

Patient Review

9/22/2016

Envarsus Xr for Prevent Kidney Transplant Rejection

I have unfortunately gained weight in my midsection since starting this medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about envarsus xr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of ENVARSUS XR?

"If you experience any of the following side effects, tell your doctor or pharmacist immediately: shaking, headache, diarrhea, nausea/vomiting, upset stomach,ordon sleeping."

Answered by AI

What is the difference between tacrolimus and Envarsus?

"ENVARSUS XR has better control over the release and absorption of tacrolimus than any other tacrolimus formulation. The MeltDose® Technology used to create ENVARSUS XR is a proprietary process that results in a controlled release of tacrolimus over a 24 hour period. This once-daily formulation overcomes the negative characteristics of other tacrolimus formulations."

Answered by AI

What is ENVARSUS XR used for?

"ENVARSUS XR helps to prevent organ rejection by reducing the body's ability to reject transplanted organs. It is an immunosuppressant, which is a type of medicine that reduces the body's immune response."

Answered by AI

Is there a generic for Envarsus?

"There is no other tacrolimus medicine that can be used as a substitute for ENVARSUS XR. The dosage for ENVARSUS XR is different from other tacrolimus products, so if you have been prescribed this medicine, make sure it is the only tacrolimus medicine you are taking."

Answered by AI

Clinical Trials for Envarsus Xr

Image of University of Oklahoma Health Campus in Oklahoma City, United States.

Disulfiram for Rheumatoid Arthritis

18 - 75
All Sexes
Oklahoma City, OK

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and systemic immune activation. Obesity is common among individuals with RA and is associated with increased disease activity, reduced treatment response, and worse functional outcomes. Inflammation in adipose tissue, driven in part by activation of the NLRP3 inflammasome and downstream gasdermin D (GSDMD)-mediated pathways, may contribute to systemic inflammation and RA disease severity. Disulfiram (DSF), an FDA-approved medication for alcohol use disorder, has recently been identified as an inhibitor of GSDMD-mediated inflammatory signaling and pyroptosis. Preclinical studies suggest that DSF reduces inflammasome activation, inflammatory cytokine release, and metabolic dysfunction. This study is a 12-week, randomized, double-blind, placebo-controlled pilot trial designed to evaluate the safety, tolerability, and preliminary efficacy of DSF in overweight and obese adults with active RA despite stable disease-modifying antirheumatic drug (DMARD) therapy. Participants will be randomized to receive either DSF (250 mg daily) or placebo. The primary objective is to assess safety and tolerability. Secondary and exploratory objectives include evaluating the effects of DSF on systemic inflammation, RA disease activity, metabolic parameters, and adipose tissue inflammasome activation. Findings from this study will inform the feasibility and design of larger clinical trials targeting GSDMD-mediated inflammation in RA.

Phase 2
Waitlist Available

University of Oklahoma Health Campus

Beatriz Y Hanaoka, MD, MSc

Image of Hopital general de Montreal in Montreal, Canada.

Nurse-led Telehealth for Rheumatoid Arthritis

18+
All Sexes
Montreal, Canada

Canada urgently needs new ways to provide rheumatology care that improve treatment and make it easier for people to get high-quality care. E-health technology is a new and promising way to do this, but it hasn't been studied much yet in rheumatology. The investigators will test a new way to help people with rheumatoid arthritis at four clinics in Quebec. This study will check if the new approach is easy to use, fits well into the clinics' daily routine, and if both patients and healthcare workers find it helpful and acceptable. This new approach involves nurses helping patients check their own health from home using an online platform. 104 adults who have rheumatoid arthritis and who have had a flare-up or a change in their medication in the last three months, will participate. Some will start using the online self-monitoring tool right away for 16 months, while others will continue with their usual care for 8 months before trying the tool. During the time they use the tool, they will fill out monthly online questionnaires to check their health. A rheumatology nurse will review their answers, suggest any needed care, provide personalized health information, and be available to answer questions through messages. This new way of care, where nurses help patients monitor their rheumatoid arthritis from home, helps make better use of limited specialist time. It's more convenient for patients, especially those who live far away, and helps meet their needs between regular doctor visits while keeping the quality of care high.

Waitlist Available
Has No Placebo

Hopital general de Montreal (+3 Sites)

Laetitia Michou, MD PhD

Image of Resilient Roots: Functional Medicine in Charlottesville, United States.

Ketogenic and Carnivore Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis

18 - 64
All Sexes
Charlottesville, VA

This study is a randomized controlled clinical trial evaluating whether two therapeutic dietary approaches - a ketogenic diet and a carnivore (lion) diet - can improve quality of life, reduce symptoms, and influence measures of disease activity in adults with inflammatory bowel disease \[ulcerative colitis and Crohn's disease\] (IBD) or rheumatoid arthritis (RA). Participants will be randomized into one of three groups: 1) Ketogenic Diet, 2) Carnivore (Lion) Diet or 3) Wait-List Control. Participants randomized to a dietary group (ketogenic diet or carnivore diet) will be provided guidance on their specific dietary therapy and answer questions about their symptoms and quality of life at different intervals over a 24 week period. Participants will also complete laboratory testing at different intervals to assess for changes in nutritional status, cardiometabolic health and markers of immune activation and inflammation. Participants initially placed on the wait-list group will be asked similar questions about their symptoms and quality of life and complete the same laboratory testing as participants in a dietary group. Participants on the wait list will then be compared to participants following a specific dietary pattern to assess for any differences between the 2 groups. After 12 weeks, participants on the wait list will be randomized to a dietary group (ketogenic diet or carnivore diet) and followed in a similar fashion for an additional 12 week period.

Recruiting
Has No Placebo

Resilient Roots: Functional Medicine

Robert D Abbott, MD

Have you considered Envarsus Xr clinical trials?

We made a collection of clinical trials featuring Envarsus Xr, we think they might fit your search criteria.
Go to Trials

Have you considered Envarsus Xr clinical trials?

We made a collection of clinical trials featuring Envarsus Xr, we think they might fit your search criteria.
Go to Trials
Image of Weill Cornell Medical College in New York, United States.

Health Coaching for Rheumatoid Arthritis

18+
All Sexes
New York, NY

The goal of this clinical trial is to learn if peer coaching works to reduce levels of anxiety and/or depression in adults diagnosed with Rheumatoid Arthritis (RA). The main questions it aims to answer are: Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months from baseline? Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months compared to those in the control arm? Researchers will compare the peer coaching intervention to an active-control arm (where people without RA coach participants on general health and nutrition topics) to see if peer coaching works to reduce anxiety and/or depression. Participants will meet with a coach every week for 9 weeks and complete several surveys before, during and after the intervention

Recruiting
Has No Placebo

Weill Cornell Medical College

Iris Y Navarro-Millán, MD

Bristol-Myers Squibb

Image of Humana Healthcare Research, Inc. in Louisville, United States.

Academic Detailing for Rheumatoid Arthritis

Any Age
All Sexes
Louisville, KY

The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab? 2. Do in-person or virtual visits work better? Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version. Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.

Waitlist Available
Has No Placebo

Humana Healthcare Research, Inc. (+1 Sites)

Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY

The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.

Phase 1 & 2
Waitlist Available

Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)

Gavin Solomon, President & CEO

Truway Health, Inc.

Have you considered Envarsus Xr clinical trials?

We made a collection of clinical trials featuring Envarsus Xr, we think they might fit your search criteria.
Go to Trials